Last updated on July 2018

Phase I/II Study of SAR422459 in Patients With Stargardt's Macular Degeneration


Brief description of study

Primary Objective:

To assess the safety and tolerability of ascending doses of SAR422459 in patients with Stargardt's Macular Degeneration.

Secondary Objective:

To evaluate for possible biological activity of SAR422459.

Detailed Study Description

The total duration per patient is up to 52 weeks, which includes a 4 week screening period and a 48 weeks study period.

At the end of the study, the patient will be invited to enter in an open-label safety study (LTS13588) and long-term follow-up visits including ophthalmological examinations and recording of adverse events for up to 15 years.

Clinical Study Identifier: NCT01367444

Contact Investigators or Research Sites near you

Start Over

Trial Transparency email recommended (Toll ...

Investigational Site Number 840002
Miami, FL United States
  Connect »

Trial Transparency email recommended (Toll ...

Investigational Site Number 840005
Iowa City, IA United States
  Connect »

Trial Transparency email recommended (Toll ...

Investigational Site Number 840001
Portland, OR United States
  Connect »

Trial Transparency email recommended (Toll ...

Investigational Site Number 840004
Houston, TX United States
  Connect »

Trial Transparency email recommended (Toll ...

Investigational Site Number 250001
Paris, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.